Compare Kaltura Inc (KLTR) vs Novavax Inc (NVAX) Price & Performance

KLTR trades at $1.59, down 3.05% today, with a bullish technical signal from moving averages and strong institutional recognition for its AI-driven digital experience platform. Revenue is stable around $181M annually, but the company remains unprofitable, with a net income margin of -6.92% in 2026. Recent earnings beats and multiple industry awards highlight operational progress amid high valuation multiples like EV/EBITDA of 336.29.

The outlook is cautiously optimistic due to consistent revenue and margin improvements, but persistent losses and high debt pose risks. Analyst sentiment is mixed with a 44.45% buy rating, suggesting potential upside if profitability is achieved, though investor caution is warranted given the negative cash flow and insider selling activity.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.